View Older Stories View More Recent Stories
-
Johnson & Johnson (JNJ) reports ERLEADA demonstrated statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration
-
Johnson & Johnson (JNJ) files for U.S. FDA approval of DARZALEX FASPRO-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned
-
Johnson & Johnson (JNJ) Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting
-
Johnson & Johnson (JNJ) reports CARVYKTI is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second lin
-
Johnson & Johnson (JNJ) reports DARZALEX-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma
-
Johnson & Johnson's (JNJ) DARZALEX FASPRO-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not p
-
J&J (JNJ): Novel combination of TALVEY and TECVAYLI suggests high response rates and durable responses in triple-class refractory patients with r/r multiple myeloma
-
Johnson & Johnson (JNJ) reports TALVEY and DARZALEX FASPRO based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma
-
Johnson & Johnson (JNJ) Announces Red River Talc Files Voluntary Chapter 11
-
Johnson & Johnson (JNJ) Gets 83% Of Baby Powder Victims To Agree To New Talc Deal - Bloomberg
-
After summer drubbing, Edwards Lifesciences (EW) said targeted in takeover - source
-
Goldman Sachs Reiterates Buy Rating on CG Oncology (CGON)
-
Johnson & Johnson (JNJ) reports dexamethasone reduced infusion-related reactions in patients with EGFR-mutated non-small cell lung cancer treated with intravenous RYBREVANT
-
Johnson & Johnson (JNJ) Announces Retirement of D. S. Davis from Board
-
Johnson & Johnson (JNJ) Reports RYBREVANT plus LAZCLUZE Showed strong favorable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
-
J&J (JNJ) Raises Settlement Offer by About $1 Billion to Roughly $9 Billion - WSJ
-
Johnson & Johnson (JNJ) seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis
-
Johnson & Johnson's (JNJ) EVP, Chief Human Resources Officer Peter Fasolo to Retire; Kristen Mulholland Named Chief Human Resources Officer, Effective October 1, 2024
-
Johnson & Johnson (JNJ) To End Some Up-Front Discounts For Hospitals - WSJ
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ) after V-Wave deal
-
Johnson & Johnson (JNJ) to acquire V-Wave in deal worth up to $1.7bn
-
Johnson & Johnson gets green light for lung cancer combination treatment
-
Johnson & Johnson (JNJ) to Acquire V-Wave
-
Johnson & Johnson (JNJ) Announces RYBREVANT plus LAZCLUZE approved in the U.S.
-
Johnson & Johnson (JNJ) Preparing to Have Subsidiary Seek Bankruptcy Protection to Consummate Talc Settlement as Soon as Next Week - Reuters
-
Johnson & Johnson (JNJ) spreader active in August 155 and August 23 weekly 155 puts
-
J&J wins plaintiff support for $6.5 billion baby powder settlement - Bloomberg
-
Johnson & Johnson (JNJ) Gets Plaintiff Backing For $6.5 Billion Baby Powder Accord - Bloomberg
-
Johnson & Johnson (JNJ) option implied volatility flat into a talc settlement draws near
-
Upside seen for Johnson & Johnson ahead of talc vote outcome
-
Daiwa Securities Downgrades Johnson & Johnson (JNJ) to Neutral (3)
-
Johnson & Johnson (JNJ) seeks U.S. FDA approval of SPRAVATO as the first and only monotherapy for adults with treatment-resistant depression
-
Johnson & Johnson (JNJ) PT Lowered to $185 at TD Cowen
-
RBC Capital Reiterates Outperform Rating on Johnson & Johnson (JNJ)
-
Johnson & Johnson (JNJ) PT Raised to $160 at Stifel
-
Midday movers: Nvidia, TSMC, Five Below, Spirit Airlines and Eli Lilly fall
-
Johnson & Johnson (JNJ) gains as Q2 earnings, revenue beat estimates
-
Johnson & Johnson (JNJ) Tops Q2 EPS by 10c, Beats on Revenue; Offers FY24 EPS Guidance
-
Stocks expected to have increasing option volume: JNJ ELV USB SYF CFG ALLY BE SAVE JBHT
-
Johnson & Johnson (JNJ) call put ratio 5.5 calls to 1 put with focus on July and August 155 calls into quarter results
-
Johnson & Johnson (JNJ) July 149 straddle into quarter results
-
JNJ Q2 earnings preview: This is what analysts expect
-
Legend Biotech said to have received takeover approach, hired Centerview - source
-
Johnson & Johnson (JNJ) Announces Completion of the Acquisition of Yellow Jersey Therapeutics, Gaining Ownership of NM26
-
Emergent BioSolutions (EBS), Johnson & Johnson (JNJ) Settle Claims Over Vaccine Manufacturing Pact - Bloomberg
-
Johnson & Johnson (JNJ) option IV flat into 2024 elections
-
Here are high-quality stock names that pay dividends
-
Johnson & Johnson (JNJ) Reports CARVYKTI achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
-
Johnson & Johnson (JNJ) reports positive results from the nipocalimab Phase 3 Vivacity-MG3 study
-
CHMP issues positive opinion for J&J's (JNJ) BALVERSA for unresectable or metastatic urothelial carcinoma
